Loading…

Prostatic Adenocarcinoma: A Grading from Gleason to the New Grade-Group System: A Historical and Critical Review

The introduction of the Gleason grading system revolutionised prognostic parameters and determination of patient treatment regiments for prostatic adenocarcinomas, and has become synonymous with prostate cancer, almost universally applied in clinical settings to predict radical prostatectomy specime...

Full description

Saved in:
Bibliographic Details
Published in:Asian Pacific journal of cancer prevention : APJCP 2019-03, Vol.20 (3), p.661-666
Main Author: Barakzai, Muhammad Abrar
Format: Article
Language:English
Subjects:
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c3561-b59db0365f58f4cfc48bee47793b5ab8192c403074f44e46ad409fa6b6ed10913
cites
container_end_page 666
container_issue 3
container_start_page 661
container_title Asian Pacific journal of cancer prevention : APJCP
container_volume 20
creator Barakzai, Muhammad Abrar
description The introduction of the Gleason grading system revolutionised prognostic parameters and determination of patient treatment regiments for prostatic adenocarcinomas, and has become synonymous with prostate cancer, almost universally applied in clinical settings to predict radical prostatectomy specimen findings, potential biochemical failure, local recurrences, lymph nodes or distant metastases in patients not receiving any treatment as well as those receiving treatment including radiation therapy, surgical treatment such as radical prostatectomy and other therapies etc,. However, characterisation and classification of prostate cancer is very different compared to 40-50 years ago when Gleason scores were first introduced. Despite this radical shift in classification, the Gleason system has remained one of the most important prognostic factors in prostate cancer, only possible as a result of timely and appropriate modifications to this characterisation system made in 2005 and 2014. However, even after these modifications, certain limitations of the Gleason system remain, due to which a new prostate cancer prognostic grade group system was introduced in 2014, which was widely accepted in the 2014 ISUP consensus conference, and incorporated into the WHO classification of thetumor of the Urinary System and Male Genital Tract in 2016. Herein, this article will discuss how this new prognostic grade group system, which is regarded as simpler and more accurate than the Gleason system risk stratification groups, will be used in conjunction with the Gleason system to improve patient prognosis and treatment.
doi_str_mv 10.31557/APJCP.2019.20.3.661
format article
fullrecord <record><control><sourceid>pubmedcentral</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6825755</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>pubmedcentral_primary_oai_pubmedcentral_nih_gov_6825755</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3561-b59db0365f58f4cfc48bee47793b5ab8192c403074f44e46ad409fa6b6ed10913</originalsourceid><addsrcrecordid>eNpVjN1KwzAAhYMobk7fwIu8QGvS_DVeCKVopwwd_oB3JU3TLdI2Jc029vbO6Y0353D4zjkAXGMUE8yYuMmWT_kyThCWB4lJzDk-AdOECh4JnnyegilmmESC8HQCLsbxCyHKUsHOwYQgieShPwXD0rsxqGA1zGrTO628tr3r1C3MYOFVbfsVbLzrYNEaNboeBgfD2sBnsztyExXebQb4th-D6X5WczsG561WLVR9DXNvwzG8mq01u0tw1qh2NFd_PgMfD_fv-TxavBSPebaINGEcRxWTdYUIZw1LG6obTdPKGCqEJBVTVYploikiSNCGUkO5qimSjeIVNzVGEpMZuPv9HTZVZ2pt-uBVWw7edsrvS6ds-Z_0dl2u3LbkacIEY-QbqaRp2A</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Prostatic Adenocarcinoma: A Grading from Gleason to the New Grade-Group System: A Historical and Critical Review</title><source>PMC (PubMed Central)</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><creator>Barakzai, Muhammad Abrar</creator><creatorcontrib>Barakzai, Muhammad Abrar</creatorcontrib><description>The introduction of the Gleason grading system revolutionised prognostic parameters and determination of patient treatment regiments for prostatic adenocarcinomas, and has become synonymous with prostate cancer, almost universally applied in clinical settings to predict radical prostatectomy specimen findings, potential biochemical failure, local recurrences, lymph nodes or distant metastases in patients not receiving any treatment as well as those receiving treatment including radiation therapy, surgical treatment such as radical prostatectomy and other therapies etc,. However, characterisation and classification of prostate cancer is very different compared to 40-50 years ago when Gleason scores were first introduced. Despite this radical shift in classification, the Gleason system has remained one of the most important prognostic factors in prostate cancer, only possible as a result of timely and appropriate modifications to this characterisation system made in 2005 and 2014. However, even after these modifications, certain limitations of the Gleason system remain, due to which a new prostate cancer prognostic grade group system was introduced in 2014, which was widely accepted in the 2014 ISUP consensus conference, and incorporated into the WHO classification of thetumor of the Urinary System and Male Genital Tract in 2016. Herein, this article will discuss how this new prognostic grade group system, which is regarded as simpler and more accurate than the Gleason system risk stratification groups, will be used in conjunction with the Gleason system to improve patient prognosis and treatment.</description><identifier>ISSN: 1513-7368</identifier><identifier>EISSN: 2476-762X</identifier><identifier>DOI: 10.31557/APJCP.2019.20.3.661</identifier><identifier>PMID: 30909661</identifier><language>eng</language><publisher>Iran: West Asia Organization for Cancer Prevention</publisher><subject>Review</subject><ispartof>Asian Pacific journal of cancer prevention : APJCP, 2019-03, Vol.20 (3), p.661-666</ispartof><rights>Copyright: © Asian Pacific Journal of Cancer Prevention 2019</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3561-b59db0365f58f4cfc48bee47793b5ab8192c403074f44e46ad409fa6b6ed10913</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6825755/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6825755/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,881,27901,27902,53766,53768</link.rule.ids></links><search><creatorcontrib>Barakzai, Muhammad Abrar</creatorcontrib><title>Prostatic Adenocarcinoma: A Grading from Gleason to the New Grade-Group System: A Historical and Critical Review</title><title>Asian Pacific journal of cancer prevention : APJCP</title><description>The introduction of the Gleason grading system revolutionised prognostic parameters and determination of patient treatment regiments for prostatic adenocarcinomas, and has become synonymous with prostate cancer, almost universally applied in clinical settings to predict radical prostatectomy specimen findings, potential biochemical failure, local recurrences, lymph nodes or distant metastases in patients not receiving any treatment as well as those receiving treatment including radiation therapy, surgical treatment such as radical prostatectomy and other therapies etc,. However, characterisation and classification of prostate cancer is very different compared to 40-50 years ago when Gleason scores were first introduced. Despite this radical shift in classification, the Gleason system has remained one of the most important prognostic factors in prostate cancer, only possible as a result of timely and appropriate modifications to this characterisation system made in 2005 and 2014. However, even after these modifications, certain limitations of the Gleason system remain, due to which a new prostate cancer prognostic grade group system was introduced in 2014, which was widely accepted in the 2014 ISUP consensus conference, and incorporated into the WHO classification of thetumor of the Urinary System and Male Genital Tract in 2016. Herein, this article will discuss how this new prognostic grade group system, which is regarded as simpler and more accurate than the Gleason system risk stratification groups, will be used in conjunction with the Gleason system to improve patient prognosis and treatment.</description><subject>Review</subject><issn>1513-7368</issn><issn>2476-762X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><recordid>eNpVjN1KwzAAhYMobk7fwIu8QGvS_DVeCKVopwwd_oB3JU3TLdI2Jc029vbO6Y0353D4zjkAXGMUE8yYuMmWT_kyThCWB4lJzDk-AdOECh4JnnyegilmmESC8HQCLsbxCyHKUsHOwYQgieShPwXD0rsxqGA1zGrTO628tr3r1C3MYOFVbfsVbLzrYNEaNboeBgfD2sBnsztyExXebQb4th-D6X5WczsG561WLVR9DXNvwzG8mq01u0tw1qh2NFd_PgMfD_fv-TxavBSPebaINGEcRxWTdYUIZw1LG6obTdPKGCqEJBVTVYploikiSNCGUkO5qimSjeIVNzVGEpMZuPv9HTZVZ2pt-uBVWw7edsrvS6ds-Z_0dl2u3LbkacIEY-QbqaRp2A</recordid><startdate>20190301</startdate><enddate>20190301</enddate><creator>Barakzai, Muhammad Abrar</creator><general>West Asia Organization for Cancer Prevention</general><scope>5PM</scope></search><sort><creationdate>20190301</creationdate><title>Prostatic Adenocarcinoma: A Grading from Gleason to the New Grade-Group System: A Historical and Critical Review</title><author>Barakzai, Muhammad Abrar</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3561-b59db0365f58f4cfc48bee47793b5ab8192c403074f44e46ad409fa6b6ed10913</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>Review</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Barakzai, Muhammad Abrar</creatorcontrib><collection>PubMed Central (Full Participant titles)</collection><jtitle>Asian Pacific journal of cancer prevention : APJCP</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Barakzai, Muhammad Abrar</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Prostatic Adenocarcinoma: A Grading from Gleason to the New Grade-Group System: A Historical and Critical Review</atitle><jtitle>Asian Pacific journal of cancer prevention : APJCP</jtitle><date>2019-03-01</date><risdate>2019</risdate><volume>20</volume><issue>3</issue><spage>661</spage><epage>666</epage><pages>661-666</pages><issn>1513-7368</issn><eissn>2476-762X</eissn><abstract>The introduction of the Gleason grading system revolutionised prognostic parameters and determination of patient treatment regiments for prostatic adenocarcinomas, and has become synonymous with prostate cancer, almost universally applied in clinical settings to predict radical prostatectomy specimen findings, potential biochemical failure, local recurrences, lymph nodes or distant metastases in patients not receiving any treatment as well as those receiving treatment including radiation therapy, surgical treatment such as radical prostatectomy and other therapies etc,. However, characterisation and classification of prostate cancer is very different compared to 40-50 years ago when Gleason scores were first introduced. Despite this radical shift in classification, the Gleason system has remained one of the most important prognostic factors in prostate cancer, only possible as a result of timely and appropriate modifications to this characterisation system made in 2005 and 2014. However, even after these modifications, certain limitations of the Gleason system remain, due to which a new prostate cancer prognostic grade group system was introduced in 2014, which was widely accepted in the 2014 ISUP consensus conference, and incorporated into the WHO classification of thetumor of the Urinary System and Male Genital Tract in 2016. Herein, this article will discuss how this new prognostic grade group system, which is regarded as simpler and more accurate than the Gleason system risk stratification groups, will be used in conjunction with the Gleason system to improve patient prognosis and treatment.</abstract><cop>Iran</cop><pub>West Asia Organization for Cancer Prevention</pub><pmid>30909661</pmid><doi>10.31557/APJCP.2019.20.3.661</doi><tpages>6</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1513-7368
ispartof Asian Pacific journal of cancer prevention : APJCP, 2019-03, Vol.20 (3), p.661-666
issn 1513-7368
2476-762X
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6825755
source PMC (PubMed Central); Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals
subjects Review
title Prostatic Adenocarcinoma: A Grading from Gleason to the New Grade-Group System: A Historical and Critical Review
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-23T23%3A01%3A08IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmedcentral&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Prostatic%20Adenocarcinoma:%20A%20Grading%20from%20Gleason%20to%20the%20New%20Grade-Group%20System:%20A%20Historical%20and%20Critical%20Review&rft.jtitle=Asian%20Pacific%20journal%20of%20cancer%20prevention%20:%20APJCP&rft.au=Barakzai,%20Muhammad%20Abrar&rft.date=2019-03-01&rft.volume=20&rft.issue=3&rft.spage=661&rft.epage=666&rft.pages=661-666&rft.issn=1513-7368&rft.eissn=2476-762X&rft_id=info:doi/10.31557/APJCP.2019.20.3.661&rft_dat=%3Cpubmedcentral%3Epubmedcentral_primary_oai_pubmedcentral_nih_gov_6825755%3C/pubmedcentral%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c3561-b59db0365f58f4cfc48bee47793b5ab8192c403074f44e46ad409fa6b6ed10913%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_id=info:pmid/30909661&rfr_iscdi=true